News | January 12, 2015

Transcatheter Technologies to Expand Platform with Tresillo Transcatheter Mitral Valve Implantation System

The premounted, valved stent is folded without the need of an outer sheath enabling precision controlled positioning and allows for repositioning

January 12, 2015 — Transcatheter Technologies GmbH has announced that it is expanding its product family to include Tresillo, a transcatheter mitral valve implantation (TMVI) version. Tresillo joins the product Trinity, a repositionable transcatheter aortic valve implantation (TAVI) system for transapical and transfemoral implantation.

Approximately 3 percent of the population older than 60 years is suffering from symptomatic mitral valve regurgitation and may benefit from a Transcatheter mitral valve implantation while avoiding open-heart surgery.

The Trinity and Tresillo systems are not approved for sale or investigational use in the United States.

For more information: www.transcatheter-technologies.com

Related Content

Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.
Feature | Heart Valve Technology | February 15, 2018
February 15, 2018 — Edwards Lifesciences Corp.
Boston Scientific Enters Investment and Acquisition Option Agreement With Millipede
News | Heart Valve Technology | January 24, 2018
Boston Scientific Corp. announced it has closed an investment and entered into an acquisition option agreement with...
Edwards LifeSciences Recalls Sapien 3 Certitude Delivery System
News | Heart Valve Technology | January 11, 2018
The U.S. Food and Drug Administration (FDA) announced that Edwards LifeSciences is recalling its Certitude Delivery...
Videos | Heart Valve Technology | January 04, 2018
Adam Greenbaum, M.D., co-director, Center for Structural Heart Disease, Henry Ford Hospital, Detroit, explains how hi
Edwards Acquires Harpoon Medical
News | Heart Valve Technology | December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology | November 15, 2017
Ted Feldman, M.D., MSCAI FACC FESC, director of the cardiac cath lab, Evanston Hospital, is the principal investigato
New Analyses Reinforce Hemodynamic Benefits of Evolut TAVR Platform in Intermediate-Risk Aortic Stenosis Patients
News | Heart Valve Technology | November 08, 2017
Medtronic plc recently presented new clinical research to support the positive clinical performance of the Evolut...
Videos | Heart Valve Technology | November 08, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Videos | Heart Valve Technology | November 08, 2017
Stephen Worthley, MB, BS, Ph.D., director of cardiac catheterization, University of Adelaide, Australia, presents the
Overlay Init